L
ipoxygenases constitute a family of lipid-peroxidizing enzymes that oxygenate free and esterified polyenolic fatty acids to the corresponding hydroperoxide derivatives. The platelet-type 12-lipoxygenase (platelet 12-LO; EC 1.13.11.31) was the first mammalian lipoxygenase discovered and is expressed in platelets, megakariocytes, and epithelial cells. 1 Platelet 12-LO catalyzes the transformation of arachidonic acid into 12-hydroperoxyeicosatetraenoic acid [12(S)-HPETE], which is reduced by different mechanisms to 12-(S)hydroxyeicosatetraenoic acid [12(S)-HETE]. 1 A dual origin for 12-HETE has been described because it also appears as an R stereoisomer, 12(R)-HETE, which is produced by cytochrome P-450. 2 A number of cardiovascular biological activities have been reported for 12(S)-HETE and 12(R)-HETE. Vascular tissue exhibits both lipoxygenase and cytochrome P-450 activities, and both 12(S)-HETE and 12(R)-HETE have been demonstrated to act as vasoconstrictors in small renal arteries. 3 In addition, a role for 12(S)-HETE in the development of angiotensin II-dependent hypertension has been described. 4 Moreover, 12(S)-HETE also participates in the modulation of angiotensin II-induced aldosterone secretion 5 and in angiotensin II-induced intracellular calcium transients in cultured rat vascular smooth muscle cells. 6 An enhanced platelet 12(S)-HETE production in the spontaneously hypertensive rat (SHR) has been recently reported. 7, 8 In addition, the pronounced and dose-dependent hypotensive effect of 12-LO inhibition observed in SHR 7 suggests that this enzyme may play a role in this form of hypertension. Recent studies have evaluated the 12(S)-HETE profile in patients with non-insulin-dependent diabetes mellitus, 9, 10 with conflicting results. On the one hand, one study reported increased urinary excretion of 12 (S)-HETE in diabetic patients as compared with control subjects. 9 In this study, there was no influence of the blood pressure level on urinary excretion of 12(S)-HETE. Moreover, a subgroup of nondiabetic patients with essential hypertension did not show increased urinary excretion of 12(S)-HETE. On the other hand, a Japanese study demonstrated that the activity of 12-LO in platelets from diabetic subjects is lower than in control subjects. 10 However, platelet production of 12(S)-HETE has not yet been reported in human hypertension.
In this study, we examined 12(S)-HETE production by platelets and the urinary 12(S)-HETE excretion in patients with essential hypertension and in normotensive control subjects. Moreover, we analyzed the protein expression of 12-LO in the different platelet subcellular localizations in hypertensive and normotensive subjects.
Methods

Study Subjects
Nineteen essential hypertensive outpatients were consecutively recruited from the Nephrology Service of the Hospital Clínic, Barcelona, Spain. The diagnosis of essential hypertension was considered on the basis that no known cause of high blood pressure could be detected after complete clinical, biochemical, and radiological examination. All the patients had Ն3 office blood pressure measurements Ͼ140/90 mm Hg after 4 weeks of an unrestricted salt diet and without antihypertensive medication. Informed consent was obtained from all the participants. Patients and control subjects were maintained on a normocaloric diet with a sodium intake of Ϸ100 mmol/d and were asked to collect a 24-hour sample of urine the day before the study. Subjects were studied in the fasting state between 8 and 10 AM. Twenty milliliters of venous blood was sampled without stasis for the measurement of platelet 12(S)-HETE and for the isolation of platelet proteins. Mean arterial blood pressure was calculated as the diastolic pressure plus one-third the pulse pressure. Body mass index (BMI) was calculated as weight (kg)/height (m) 2 . Nine volunteer subjects with no history of hypertension or cardiovascular disease with blood pressure Ͻ130/80 mm Hg in 3 separate determinations were selected as normotensive control subjects.
Platelet Preparation
Human platelets were isolated in polypropylene tubes from blood anticoagulated with ACD (in mmol/L: 3.8 citric acid, 7.5 trisodium citrate, and 13.6 dextrose) at a ratio of 9:1 (blood:ACD) from 9 healthy donors and 9 patients with essential hypertension who had not taken aspirin (or other medications) for Ն10 days. To obtain platelet-rich plasma, the blood was centrifuged at 200g for 15 minutes at room temperature. The platelet-rich plasma was carefully collected by aspiration and was then centrifuged at 1200g for 15 minutes. Plasma was removed, and the platelet pellet was washed twice in Tyrode's-HEPES buffer and 14 mmol/L EDTA. Isolated platelets were resuspended in 2 mL Tyrode's-HEPES buffer, and the sample was mixed by inversion. One aliquot of 900 L (aliquot A) was incubated with 1 U/mL thrombin (Sigma-Aldrich, Germany) for 30 minutes at 37°C, and the second aliquot was incubated without thrombin (aliquot B). After the incubation, 2 volumes of methanol were added to both aliquots and the samples were stored at Ϫ20°C until the assay. Finally, an aliquot of 50 L was used to determine platelet count number in a Neubauer chamber.
12(S)-HETE Production in Platelets
To measure 12(S)-HETE generation from platelets, 50 L of the supernatants of aliquots A and B were evaporated with N 2 , and the residue was resuspended with 250 L of ice-cold EIA phosphate buffer containing 0.01 mol/L phosphate, 0.9% NaCl, 0.1% MgCl 2 , 0.1% BSA, and 0.1% sodium azide at pH 7.4. The levels of 12(S)-HETE in urine and in platelet incubations were measured by ELISA (DRG Diagnostica) after extraction of samples on Sep-Pak C 18 cartridges (Waters). The 12-HETE ELISA is specific for 12(S)-HETE, with Ͻ2.5% cross-reactivity with 12(R)-HETE, 0.3% with 15-HETE, 0.2% with 5-HETE, 0.1% with PGE 2 , and 0.1% with PGI 2 . 12(S)-HETE levels in platelet incubations were also determined by reverse-phase (RP) high-performance liquid chromatography (HPLC). 11 Briefly, Sep-Pack-extracted samples from platelet suspensions were injected into an RP-HPLC system that consisted of a Waters integrated system controller (model 600E) equipped with a 996-photodiode array detector and a Millennium HPLC analysis software. For analysis of 12(S)-HETE, a Tracer Kromasil 100 C 18 (5 m, 4.6ϫ250 mm) column eluted with MeOH/H 2 O/acetic acid (65:35:0.01; vol/vol/vol) as phase 1 (t 0 to 20 minutes) and a linear gradient with MeOH/acetic acid (99.9:0.1, vol/vol) as phase 2 (20 to 45 minutes) at a flow rate of 1.0 mL/min was used, and the UV detector was set at 234 nm.
Subcellular Fractionation of Platelets and Detection of 12-LO Protein
Platelets were resuspended in sonication buffer consisting of (in mmol/L): 100 KCl, 15 NaCl, 12 sodium citrate, 2 MgSO 4 , 10 glucose, and 25 HEPES, plus 0.2 mmol/L PMSF, 0.5 g/mL leupeptin, 0.7 g/mL pepstatin A, 0.05 U/mL aprotinin, and 1 mmol/L DTT at pH 7.5. All subsequent steps were carried out at 4°C. The cells were sonicated for 60 seconds and the lysate was subjected to centrifugation at 4000g for 5 minutes. The supernatant was further centrifuged at 100 000g for 75 minutes, and the supernatant was regarded as cytosolic fraction and the pellet as membrane fraction, which was resuspended in 1 mL of Tyrode's-HEPES buffer with protease inhibitors and 1% of SDS. Protein content of all samples was determined by the Bradford method. 12 Protein (10 g) of the subcellular fractions was subjected to SDS-PAGE on 10% polyacrylamide 13 gels and transferred to a polyvinylidene difluoride (PVDF) membrane. Preliminary 10% SDS-polyacrylamide gels were run and were stained with Coomassie blue to confirm equality of loading in each lane. The PVDF membranes were incubated with a 1:1000 final dilution of rabbit polyclonal antiserum (Cayman Chemical) against human platelet 12-LO for 60 minutes. The immunocomplexes were detected by the enhanced chemiluminescence method (Amersham). The blots were quantified by densitometry (Non Linear Dynamics Ltd). The band density values were normalized by dividing by the mean value for the control subjects and multiplying by 100%.
Determination of Urinary 12(S)-HETE, Prostaglandins, and Urinary Albumin Excretion
Urinary 12(S)-HETE was determined as detailed above for the platelet incubations. Prostaglandin (PG)E 2 and 6-keto-PGF 1␣ levels in urine were analyzed by ELISA (Amersham International) after extraction of samples on Sep-Pack C 18 cartridges. Urinary albumin excretion rate from 2 separate 24-hour urine collections was measured with an immunonephelometric assay (Boehringer Mannheim). Microalbuminuria was defined as urinary albumin excretion rate between 20 and 200 g/min.
Statistical Analysis
Data are presented as meanϮSEM. Comparisons between means were determined by 2-sided Mann-Whitney U test for unpaired data. Correlation coefficients were calculated by the least-squares method. The 5% probability level was regarded as significant.
Results
The clinical characteristics of the patients with essential hypertension and the normotensive control subjects are shown in the Table. There were no major differences or significant trend in the age and gender distribution among groups. Likewise, urinary sodium excretion was similar in both groups. Urinary albumin excretion was measured in the patients with hypertension, and the mean value was 8.5Ϯ2 g/min (range, 2 to 39).
The in vitro platelet generation of 12(S)-HETE was measured in basal conditions and after stimulation with human thrombin in patients and control subjects. The basal generation of 12(S)-HETE was significantly higher in patients with essential hypertension than in the normotensive individuals: 3.56Ϯ1.22 versus 0.64Ϯ0.13 ng/10 6 platelets (PϽ0.025) ( Figure 1A, left) . There were no significant differences between patients with essential hypertension and control subjects in the thrombin-stimulated 12(S)-HETE platelet generation: 7.66Ϯ2.14 versus 4.87Ϯ1.46 ng/10 6 platelets (Pϭ0.61) ( Figure 1A , right). Figure 2 shows representative chromatograms obtained during HPLC analysis of plasma from a control subject and a patient with essential hypertension.
To investigate the possible mechanism of increased platelet production of 12(S)-HETE in essential hypertension, the amount of 12-LO protein was measured in the platelet cytosolic and membrane fractions by Western blotting in 9 patients and 9 control subjects. Most of the 12-LO protein expression in platelets was observed in the cytosolic fraction rather than in the membrane fraction. Patients with essential hypertension displayed significantly higher levels of 12-LO protein in the cytosolic fraction: 240Ϯ46 versus 106Ϯ27% (Pϭ0.032) ( Figure 1B, a) . Although the 12-LO protein level in the membrane fraction was also higher in patients than in control subjects (155Ϯ29 versus 87Ϯ18%), the difference was not statistically significant (Pϭ0.07) ( Figure 1B, b) .
Urinary 12(S)-HETE excretion as measured in relation to creatinine excretion was significantly higher in patients with essential hypertension (nϭ19) than in the control subjects (nϭ9): 36.8Ϯ7.24 versus 17.1Ϯ3.14 ng/mg creatinine (PϽ0.05) (Figure 3, left) . Urinary excretion of PGE 2 and the hydrolysis product of PGI 2 (6-keto-PGF 1␣ ) were also measured in patients and control subjects. There were no significant differences in the levels of PGE 2 excretion between patients and control subjects: 1.56Ϯ0.2 versus 1.37Ϯ0.16 ng/mg creatinine (Pϭ0.57) (Figure 3, right) . In contrast, patients with essential hypertension displayed a significantly reduced PGI 2 excretion as compared with the normotensive control subjects: 0.499Ϯ0.05 versus 0.685Ϯ0.07 ng/mg creatinine (PϽ0.05) (Figure 3 , center). The 12(S)-HETE/PGI 2 ratio was significantly higher in patients than in control subjects: 76Ϯ19 versus 28Ϯ7 (PϽ0.05). There was no correlation between blood pressure, age, gender, plasma renin activity, or aldosterone and the urinary excretion of 12(S)-HETE, PGI 2 , or PGE 2 or the basal and stimulated platelet production of 12(S)-HETE. On the contrary, in the patients with essential hypertension, urinary excretion of PGI 2 was positively correlated with the urinary albumin excretion (rϭ0.67, PϽ0.02) and inversely correlated with the BMI (rϭϪ0.74, PϽ0.05).
Clinical Characteristics of Patients and Control Subjects Studied
Discussion
In this study, we observed that the production of 12(S)-HETE by platelets from patients with essential hypertension is higher than in normotensive control subjects. The platelet 12-LO protein amount in the cytosolic fraction of platelets from hypertensive patients was higher than in the control subjects. In addition, the patients with essential hypertension excreted higher amounts of 12(S)-HETE and lower amounts of the vasodilatory prostaglandin PGI 2 in the urine than did the normotensive control subjects.
Arachidonic acid is metabolized through the cyclooxygenase, lipoxygenase (LO), and the cytochrome P-450 pathways. The role of cyclooxygenase or cytochrome P-450 metabolites in cardiovascular physiology and hypertension has been intensively studied in the last years. 14 In contrast, the possible role of LO metabolites in hypertension has been less explored. Several studies have demonstrated that the administration of the LO inhibitors phenidone and 5,8,11-eicosatriyonic acid reduces blood pressure in several rat models of hypertension such as the SHR and the 2-kidney, 1-clip Goldblatt rats. This response to LO inhibition suggests a role for LO metabolites in the pathogenesis of experimental hypertension. 4, 7, 8 12(S)-HETE displays vascular actions that are in agreement with their prohypertensive functions. 3 In addition, treatment with LO inhibitors attenuates the vasoconstrictor action of angiotensin II in hypertensive rats. 15 Evidence of enhanced 12-LO activity in the SHR has been recently provided. 7 The basal 12(S)-HETE production by platelets was higher in the SHR than in the control WistarKyoto rats. Moreover, there was a striking correlation between platelet 12(S)-HETE production and systolic blood pressure. Confirming previous results, the administration of a LO inhibitor reduced blood pressure in the SHR, with a concomitant reduction in the platelet production of 12(S)-HETE. 7 In addition, increased 12-HETE production has also been demonstrated in the aortas of the SHR. 8 However, the mechanisms of the enhanced production of 12(S)-HETE in experimental hypertension has yet not been elucidated.
The role of 12(S)-HETE in human hypertension has not been directly explored. It has been reported that vascular smooth muscle and endothelial cells from patients with diabetes mellitus have increased release of 12-and 15-HETE, 16 suggesting a role for this metabolite in this disease. Our finding of a higher basal platelet production and urinary excretion of 12(S)-HETE in a group of patients with essential hypertension is in agreement with the results obtained in rat models of hypertension as detailed above 7, 8 but is in contrast with previous studies measuring urinary 12(S)-HETE in humans. 9 Although the focus of that study was non-insulindependent diabetes mellitus, the authors evaluated urinary excretion of 12(S)-HETE in a group of 9 patients with essential hypertension and found no differences as compared with healthy control subjects. 9 Increased urinary excretion of 12(S)-HETE may reflect either higher renal production of this metabolite because it can be synthesized in glomeruli and tubuli 17 or higher plasma concentration or both. The concomitant decreased urinary excretion of PGI 2 in patients with essential hypertension is striking. It has been demonstrated that HETEs can suppress PGI 2 in vitro as well as inhibit vascular cyclooxygenase. 16 In this sense, decreased urinary excretion of PGI 2 in concordance with increased urinary 12(S)-HETE excretion has also been shown in diabetic patients. 9 Such high ratios of HETE/prostanoids have been found in the urine of cirrhotic patients 18 and in the bronchoalveolar lavage fluid of asthmatic patients after aspirin challenge. 19 In this study, the higher amounts of platelet 12-LO protein in platelet cytosolic fraction from patients with hypertension suggest a possible mechanism underlying the higher platelet 12(S)-HETE production. However, in addition to higher protein expression, other mechanisms may operate because the difference in protein expression between patients and control subjects was comparatively less than the 5-fold difference in platelet 12(S)-HETE production observed between the groups. We found a predominant localization of 12-LO protein in the cytosol, and the difference in the amount of this protein between patients and control subjects was more marked in the cytosolic than in the membrane fraction. The intracellular distribution of 12-LO activity varies between different cells, ranging from a predominant cytosolic 20 localization to a preferential localization in membranes. 21 In human platelets, most 22 but not all 23 investigators have observed a predominant (65%) localization of 12-LO activity and protein in the cytosolic fraction. 12(S)-HETE has also been shown to participate in the regulation of platelet function such as aggregation and P-selectin expression. 23 Moreover, a newly developed platelet adhesion inhibitor, OPC-29030, dose-dependently inhibits the production of 12(S)-HETE but not the synthesis of thromboxane B 2 . 23 This finding may be important because it is known that in essential hypertension, platelets display enhanced secretory and aggregatory responses, reflecting a hyperactivated state 24 that may play a crucial role in the atherosclerotic process relevant in patients with this disease. Moreover, 12-HETE has been shown in endothelial cells to have mitogenic properties. 25 It is interesting that 12-HETE production has been found to be increased in small vessels from ischemic kidneys, thus reflecting renal tissue injury. 3 In summary, our results indicate that urinary excretion and platelet production of 12(S)-HETE is increased in patients with essential hypertension. The higher levels of 12-LO protein displayed by platelets from patients with hypertension suggest a possible mechanism mediating the increase in 12(S)-HETE. These findings might have clinical implications regarding the platelet disturbances observed in essential hypertension.
